Real-world practice of the Egyptian Kelleni's protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants : a multi-purpose protocol
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
The Egyptian immune-modulatory Kelleni's protocol, including nitazoxanide as an integral component, is being safely and effectively practiced to manage SARS-CoV-2, RSV, influenza infections in pediatric, adult and pregnant patients with negligible requirements for the relatively expensive diagnostic molecular tests. Most recently, Kelleni's protocol is being likewise used to manage potential norovirus infection which is currently confused with SARS-CoV-2 Omicron new enterotropic subvariants and the antihistaminic loratadine has been co-administered in selected patients. Notably, Africa has the least mandates, restrictions and SARS-CoV-2 vaccination rates and yet the least COVID-19 mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 31(2023), 3 vom: 01. Juni, Seite 1559-1560 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kelleni, Mina T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 01.06.2023 Date Revised 18.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10787-023-01180-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354341243 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354341243 | ||
| 003 | DE-627 | ||
| 005 | 20240119231834.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-023-01180-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1264.xml |
| 035 | |a (DE-627)NLM354341243 | ||
| 035 | |a (NLM)36928633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kelleni, Mina T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world practice of the Egyptian Kelleni's protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants |b a multi-purpose protocol |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2023 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a The Egyptian immune-modulatory Kelleni's protocol, including nitazoxanide as an integral component, is being safely and effectively practiced to manage SARS-CoV-2, RSV, influenza infections in pediatric, adult and pregnant patients with negligible requirements for the relatively expensive diagnostic molecular tests. Most recently, Kelleni's protocol is being likewise used to manage potential norovirus infection which is currently confused with SARS-CoV-2 Omicron new enterotropic subvariants and the antihistaminic loratadine has been co-administered in selected patients. Notably, Africa has the least mandates, restrictions and SARS-CoV-2 vaccination rates and yet the least COVID-19 mortality | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Influenza | |
| 650 | 4 | |a Kelleni’s protocol | |
| 650 | 4 | |a Loratadine | |
| 650 | 4 | |a Nitazoxanide | |
| 650 | 4 | |a Norovirus | |
| 650 | 4 | |a RSV | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d 1996 |g 31(2023), 3 vom: 01. Juni, Seite 1559-1560 |w (DE-627)NLM090686616 |x 1568-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:3 |g day:01 |g month:06 |g pages:1559-1560 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10787-023-01180-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 3 |b 01 |c 06 |h 1559-1560 | ||